Dimensional Fund Advisors LP Has $53.54 Million Position in Protagonist Therapeutics, Inc. $PTGX

Dimensional Fund Advisors LP raised its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 22.6% in the first quarter, Holdings Channel reports. The fund owned 508,103 shares of the company’s stock after acquiring an additional 93,688 shares during the period. Dimensional Fund Advisors LP’s holdings in Protagonist Therapeutics were worth $53,542,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Protagonist Therapeutics by 27.2% in the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after purchasing an additional 1,156,461 shares during the last quarter. State Street Corp boosted its position in Protagonist Therapeutics by 18.5% in the second quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after buying an additional 500,924 shares in the last quarter. Wellington Management Group LLP boosted its position in Protagonist Therapeutics by 66.2% in the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after buying an additional 1,262,977 shares in the last quarter. UBS Group AG grew its stake in Protagonist Therapeutics by 46.1% during the fourth quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock worth $241,934,000 after buying an additional 874,013 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in Protagonist Therapeutics by 140.7% during the fourth quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock worth $231,355,000 after buying an additional 1,549,160 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Zacks Research raised shares of Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Truist Financial boosted their target price on Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings restated a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Johnson Rice set a $165.00 price target on Protagonist Therapeutics in a report on Friday, July 17th. Finally, TD Cowen reiterated a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Bryan Giraudo sold 6,000 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $100.00, for a total transaction of $600,000.00. Following the transaction, the director owned 31,825 shares of the company’s stock, valued at approximately $3,182,500. This represents a 15.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the transaction, the chief executive officer directly owned 523,478 shares in the company, valued at approximately $52,410,617.36. This represents a 12.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 161,130 shares of company stock valued at $16,355,220 over the last quarter. Corporate insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Stock Down 1.4%

Shares of NASDAQ:PTGX opened at $136.64 on Friday. The firm has a market cap of $8.79 billion, a P/E ratio of -75.49 and a beta of 1.79. Protagonist Therapeutics, Inc. has a 12 month low of $50.49 and a 12 month high of $143.29. The company’s 50-day moving average price is $120.38 and its two-hundred day moving average price is $103.23.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The company had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. As a group, equities analysts predict that Protagonist Therapeutics, Inc. will post 3.69 earnings per share for the current fiscal year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.